BioMarin Pharmaceutical (BMRN) is highlighted as a potential growth stock by Zacks, despite its current #3 (Hold) Zacks Rank, driven by an "A" VGM Score and a "B" Growth Style Score. The company projects 25.3% year-over-year earnings growth for the current fiscal year, supported by 10 analyst upward revisions for fiscal 2025 earnings estimates over the last 60 days, which increased the Zacks Consensus Estimate to $4.41 per share, alongside a historical average earnings surprise of 25.7%.
BioMarin Pharmaceutical (BMRN) presents a compelling case for growth investors, supported by strong fundamental metrics despite a neutral Zacks Rank of #3 (Hold). The company is forecasted to deliver significant year-over-year earnings growth of 25.3% for the current fiscal year and has a demonstrated history of exceeding expectations with an average earnings surprise of 25.7%. Forward-looking sentiment appears positive, as evidenced by ten upward analyst revisions for fiscal 2025 earnings over the last 60 days, which has pushed the consensus estimate up to $4.41 per share. According to the provided framework, BMRN's profile is further bolstered by a top-tier 'A' VGM Score and a strong 'B' Growth Style Score, indicating that its underlying growth and momentum characteristics are favorable even if its overall rank suggests a neutral short-term outlook.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
strongly positive
Sentiment Score
0.75
Ticker Sentiment
